• Senior Couple - Daughter
  • Senior Couple
  • Senior - Child
  • Doctor - Young People
  • Doctor - Child
Med BioGene Inc. Appoints Bruce Cousins as a Director
June 05, 2006

VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (“MBI?) (TSX Venture: MBI) is pleased to announce the appointment of Bruce Cousins, C.A., as a director of MBI.

Mr. Cousins is the Chief Financial Officer of Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) (www.aspreva.com). With Mr. Cousins as its CFO, Aspreva completed a $76 million private equity financing and a $113 million cross-border initial public offering on the Nasdaq National Market and Toronto Stock Exchange—the largest initial public offering for a biotechnology / biopharmaceutical company in Canadian history. Furthermore, during his tenure, Mr. Cousins has seen Aspreva evolve into an emerging global biopharmaceutical company with expected 2006 revenues to exceed US$200 million.

Prior to joining Aspreva, Mr. Cousins spent 14 years with Johnson & Johnson (J&J) as the World Wide Financial Director for J&J's Wound Management Division in Somerville, New Jersey. As CFO of this US$500 million business unit, Mr. Cousins also held a key leadership role on the Global Management Board. Prior to entering the pharmaceutical industry, Mr. Cousins was a chartered accountant with Deloitte & Touche.

“Bruce’s experience and accomplishments in the industry will be invaluable in assisting Med BioGene’s efforts to develop its molecular diagnostic tests? stated Erinn Broshko, Chief Executive Officer of MBI. “Bruce greatly adds to our already strong board of directors and his appointment reflects positively on Med BioGene’s future prospects.?

“I am delighted to join Med BioGene at such an exciting time in the company’s growth,? stated Mr. Cousins. “With a highly qualified scientific and senior management team in place and a solid intellectual property portfolio, Med BioGene is well-positioned to be a leader in molecular diagnostics. I look forward to working with the other board members and senior management to make Med BioGene a success.?

Corporate Matters

MBI has granted five-year incentive stock options to purchase an aggregate of 150,000 common shares at an exercise price of $0.40 per share.

About Med BioGene

MBI is a biotechnology company with advanced research expertise in gene expression technology. MBI’s mission is to become a market leader in the supply of content for molecular-based diagnostic micro arrays. MBI intends to fulfill this mission by developing and marketing genetic content for molecular-based human diagnostic tests. Molecular diagnostics, based on genetic expression, is a developing technology field that has the potential to replace certain of today’s standard diagnostic tests. MBI intends to utilize its expertise in gene expression, bioinformatics and micro arrays to develop the diagnostic tests’ genetic content. From the tens of thousands of genes in the human genome, MBI is attempting to identify those genes, known as "bio markers," which mark the presence of various disease conditions.

MBI’s initial focus will be developing diagnostic tests for certain types of cancer, specifically lymphoma and leukemia. In the future, MBI intends to develop diagnostic tests to identify the earliest stages of heart disease or the presence of an infectious disease. These diagnostic test kits will be designed to provide additional information to physicians to allow them to create more suitable and more effective treatments for an improved patient prognosis.

For further information, please contact:

Erinn B. Broshko
Chief Executive Officer
(604) 306-4969
ebroshko@medbiogene.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation. Words such as “anticipates,? “believes,? “estimates,? “expects,? “intends,? “may,? “plans,? “projects,? “will,? “would? and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but are not limited to, those with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements or information are only predictions based upon MBI’s current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI’s actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. Our forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.


Home|About Us|Careers|News|Contact

© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer